

P&T Motion History Targeted Immune Modulators (TIMs)

Drugs reviewed	Motion	Date reviewed	Surveillance accepted as adequate	Reiteration of prior motion	Decision
baricitinib guselkumab risankizumab tildrakizumab upadacitinib abatacept adalimumab anakinra apremilast brodalumab certolizumab pegol etanercept golimumab infliximab ixekizumab natalizumab rituximab sarilumab secukinumab tocilizumab tofacitinib ustekinumab vedolizumab	<p>After considering the evidence of safety, efficacy, effectiveness and special populations for the use of targeted immune modulators for their FDA approved indications, I move that: baricitinib, guselkumab, risankizumab, tildrakizumab, upadacitinib, abatacept, adalimumab, anakinra, apremilast, brodalumab, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, natalizumab, rituximab, sarilumab, secukinumab, tocilizumab, tofacitinib, ustekinumab, vedolizumab are efficacious. The PDL must include a drug approved for treatment of the following FDA indications (rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis) and must include a self-administered agent if indicated.</p> <p>These medications cannot be subject to therapeutic interchange in the Washington preferred drug list.</p> <p>Motion: Park 2nd: Storhaug</p>	April 21, 2021	Yes Park Lee	Yes Flatebo Brown	Passed unanimous